Results 11 to 20 of about 365 (119)

An open-label pilot study on an adsorbent mousse containing adelmidrol in client-owned cats with feline atopic skin syndrome and associated seborrhoea. [PDF]

Vet Dermatol
Background – Besides pruritus and skin lesions, cats with feline atopic skin syndrome (FASS) may have seborrhoea. Hypothesis/Objectives – The aim of this pilot study was to investigate whether an adsorbent mousse containing tapioca starch, adelmidrol and a nonpharmacological antimicrobial complex could decrease FASS‐associated seborrhoea in cats ...
Noli C, Della Valle MF, Morelli G, Schievano C, Skinalia Clinical Research Group.   +4 more
europepmc   +2 more sources

Efficacy and field safety of ilunocitinib for the control of atopic dermatitis in client-owned dogs: A multicentre, double-masked, randomised, placebo-controlled clinical trial. [PDF]

Vet Dermatol
Background – Inhibition of the Janus kinase (JAK) pathway is a well‐established option for canine atopic dermatitis (cAD). Objective – To evaluate the efficacy and safety of ilunocitinib, a novel JAK inhibitor for the control of pruritus and skin lesions in client‐owned dogs with cAD.
Forster S, Trout CM, Despa S, Boegel A, Berger D, King S.   +5 more
europepmc   +2 more sources

Efficacy and Field Safety of Ilunocitinib for the Control of Allergic Dermatitis in Client-Owned Dogs: A Multicenter, Double-Masked, Randomised, Placebo-Controlled Clinical Trial. [PDF]

Vet Dermatol
Background: Inhibition of the Janus kinase pathway is an established treatment for allergic dermatitis. Objective: To evaluate the efficacy and safety of ilunocitinib for control of pruritus in dogs with allergic dermatitis in a randomised, double‐masked clinical trial.
Forster S, Trout CM, Despa S, Boegel A, Berger D, King S.   +5 more
europepmc   +2 more sources

Validación del ClinESSDAI para Argentina

Revista Argentina de Reumatología, 2023
Introducción: recientemente, en Europa y en idioma inglés, se ha desarrollado el Clinical EULAR Sjögren's Syndrome Disease Activity Index (ClinESSDAI) para evaluar la actividad en pacientes con síndrome de Sjögren primario (SSp).
Julieta Silvana Morbiducci, María Florencia Rodríguez, Patricia Sasaki, Agustina Cáceres, Lucía Alascio, Silvia Papasidero, Sinda Zalles, Julia Demarchi, Anastasia Secco   +8 more
doaj   +1 more source

Bloqueo capsular versus bloqueo IPACK: Comparación en el manejo del dolor en pacientes con reemplazo total de rodilla

Revista Científica CMDLT, 2022
Objetivo: Evaluar la eficacia del bloqueo capsular versus bloqueo IPACK en el manejo del dolor en pacientes tratados con reemplazo total de rodilla.
Julio Alfonso García Hernández, Franco Cordivani Maloni   +1 more
doaj   +5 more sources

Comparative efficacy and safety of ilunocitinib and oclacitinib for the control of pruritus and associated skin lesions in dogs with atopic dermatitis. [PDF]

Vet Dermatol
Background – Janus kinase inhibitors (JAKi) have been shown to reduce pruritus and improve associated inflammatory skin lesions in canine atopic dermatitis (cAD). Objective – To evaluate the efficacy and safety of ilunocitinib, in comparison to oclacitinib, for the control of cAD in a randomised, blinded trial.
Forster S, Boegel A, Despa S, Trout C, King S.   +4 more
europepmc   +2 more sources

A prospective study evaluating the correlation between local weather conditions, pollen counts and pruritus of dogs with atopic dermatitis. [PDF]

Vet Dermatol
Abstract Background Canine atopic dermatitis (cAD) is a hereditary, generally pruritic and predominantly T‐cell‐driven inflammatory skin disease, involving an interplay between skin barrier abnormalities, allergen sensitisation and microbial dysbiosis.
Widorn L, Zabolotski Y, Mueller RS.
europepmc   +2 more sources

A randomised, double‐blinded, controlled trial to determine the efficacy of combined therapy of oclacitinib and marine oil extract PCSO‐524 in dogs with atopic dermatitis

Veterinary Dermatology, Volume 34, Issue 6, Page 523-531, December 2023., 2023
Background – Polyunsaturated fatty acids (PUFA) can be beneficial in the management of canine atopic dermatitis (cAD). A commercial product PCSO‐524 containing PUFA has demonstrated anti‐inflammatory effects in dogs. Hypothesis/Objectives – To evaluate the efficacy of PCSO‐524, in combination with oclacitinib in dogs with cAD.
Takeo Nishiyama, Masashi Kusakabe, Ichiro Imanishi, Tadashi Hisano, Teruyasu Fukamachi, Norihito Taguchi, Keita Iyori, Yun‐Hsia Hsiao   +7 more
wiley   +1 more source

Dolor postoperatorio en cirugía de reparación del manguito rotador mini abierto y artroscópico bajo protocolo de analgesia multimodal

Revista Colombiana de Ortopedia y Traumatología, 2020
Introducción: La cirugía de manguito rotador ha mejorado los síntomas y la función asociada a las lesiones que no han respondido al manejo conservador, sin embargo, puede presentarse dolor severo e incomodidad en el postoperatorio requiriendo una ...
Luis José María Suárez, Guido Fierro P, Juan Carlos González G   +2 more
doaj   +1 more source

A randomised controlled trial testing the rebound‐preventing benefit of four days of prednisolone during the induction of oclacitinib therapy in dogs with atopic dermatitis

Veterinary Dermatology, Volume 34, Issue 2, Page 99-106, April 2023., 2023
Background – A rebound of pruritus occasionally occurs after oclacitinib dose reduction in dogs with atopic dermatitis (AD). Objectives – To determine whether an initial 4‐day course of prednisolone decreases the probability of a pruritus rebound after reducing the frequency of oclacitinib administration.
Thierry Olivry, Viktorija Lokianskiene, Alejandro Blanco, Pablo Del Mestre, Kerstin Bergvall, Luc Beco   +5 more
wiley   +1 more source